drugset / Trial / NCT05290155
Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies
Phase 1
Completed
14 enrolled
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of CAR T cell treatment targeting CD7 in patients with relapsed or refractory CD7 positive T-cell hematological maliganacies
Timeline
- Start
- 2022-05-04
- Primary completion
- 2024-08-01
- Completion
- 2025-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | anti-CD7 CAR-T cells | Cell therapy | 250000 cells/kg | — |
| Subject | anti-CD7 CAR-T cells | Cell therapy | 500000 cells/kg | — |
| Subject | anti-CD7 CAR-T cells | Cell therapy | 1e+06 cells/kg | — |